HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE
While hydroxycarbamine (hydroxyurea, HU) has less and less indications in malignant hemopathies, it represents the only widely used drug which modifies sickle cell disease pathogenesis. Clinical experience with HU for patients with sickle cell disease has been accumulated over the past 25 years in W...
Saved in:
| Main Authors: | Giovanna Cannas, Solene Poutrel, Xavier Thomas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2017-02-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2820 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy
by: Gabriela Araujo de Abreu, et al.
Published: (2024-11-01) -
Sickle Cell Anemia Treatment With Hydroxyurea in Low-Resource Settings: Challenges and Opportunities for Global North-South Collaboration
by: Teresa S. Latham
Published: (2025-01-01) -
Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial
by: Vincent Mboizi, et al.
Published: (2024-12-01) -
Prevalence and predictors of Sickle Cell Nephropathy A single-center experience
by: Khaled Elzorkany, et al.
Published: (2024-11-01) -
Caregivers’ Perceived Threat Of Sickle Cell Disease Complications And Its Association With Hydroxyurea Use Among Children With Sickle Cell Disease In Dar Es Salaam, Tanzania
by: Ally M, et al.
Published: (2024-12-01)